Skip to main content
NCBI home page
Bulletin of the World Health Organization logoLink to Bulletin of the World Health Organization
. 1995;73(1):33–40.

Risk of vaccine-associated paralytic poliomyelitis in Latin America, 1989-91.

J K Andrus 1, P M Strebel 1, C A de Quadros 1, J M Olivé 1
PMCID: PMC2486585  PMID: 7704923

Abstract

A major factor influencing the success of poliomyelitis eradication in the Americas was the reliance on mass immunization campaigns with oral poliovirus vaccine (OPV). As global poliomyelitis eradication activities accelerate and campaign vaccine delivery strategies are applied elsewhere, it is critical to determine whether the risk of vaccine-associated paralytic poliomyelitis (VAPP) is altered when routine delivery strategies are supplemented with mass immunization campaigns. We analysed all 6043 cases of acute flaccid paralysis (AFP) reported in Latin America over the period 1989-91 in order to estimate the risk of VAPP. The overall risk was estimated to be one case per 1.5-2.2 million doses of OPV administered, compared with one case per 1.4 million doses administered in England and Wales (1985-91) and with one case per 2.5 million net doses distributed in the USA (1980-89). These data suggest that to eradicate poliomyelitis globally, strategies that rely on mass immunization campaigns to supplement routine delivery services, as recommended by WHO, do not appear to alter significantly the risk of VAPP.

Full text

PDF
33

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andrus J. K., de Quadros C., Olivé J. M., Hull H. F. Screening of cases of acute flaccid paralysis for poliomyelitis eradication: ways to improve specificity. Bull World Health Organ. 1992;70(5):591–596. [PMC free article] [PubMed] [Google Scholar]
  2. Asbury A. K., Cornblath D. R. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol. 1990;27 (Suppl):S21–S24. doi: 10.1002/ana.410270707. [DOI] [PubMed] [Google Scholar]
  3. Centers for Disease Control (CDC) Update: eradication of paralytic poliomyelitis in the Americas. MMWR Morb Mortal Wkly Rep. 1992 Sep 11;41(36):681–683. [PubMed] [Google Scholar]
  4. De Quadros C. A., Andrus J. K., Olivé J. M., Da Silveira C. M., Eikhof R. M., Carrasco P., Fitzsimmons J. W., Pinheiro F. P. Eradication of poliomyelitis: progress in the Americas. Pediatr Infect Dis J. 1991 Mar;10(3):222–229. doi: 10.1097/00006454-199103000-00011. [DOI] [PubMed] [Google Scholar]
  5. Joce R., Wood D., Brown D., Begg N. Paralytic poliomyelitis in England and Wales, 1985-91. BMJ. 1992 Jul 11;305(6845):79–82. doi: 10.1136/bmj.305.6845.79. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Ropper A. H. The Guillain-Barré syndrome. N Engl J Med. 1992 Apr 23;326(17):1130–1136. doi: 10.1056/NEJM199204233261706. [DOI] [PubMed] [Google Scholar]
  7. Strebel P. M., Sutter R. W., Cochi S. L., Biellik R. J., Brink E. W., Kew O. M., Pallansch M. A., Orenstein W. A., Hinman A. R. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis. 1992 Feb;14(2):568–579. doi: 10.1093/clinids/14.2.568. [DOI] [PubMed] [Google Scholar]
  8. da Silva E. E., Pallansch M. A., Holloway B. P., Oliveira M. J., Schatzmayr H. G., Kew O. M. Oligonucleotide probes for the specific detection of the wild poliovirus types 1 and 3 endemic to Brazil. Intervirology. 1991;32(3):149–159. doi: 10.1159/000150195. [DOI] [PubMed] [Google Scholar]
  9. de Quadros C. A., Andrus J. K., Olive J. M., Guerra de Macedo C., Henderson D. A. Polio eradication from the Western Hemisphere. Annu Rev Public Health. 1992;13:239–252. doi: 10.1146/annurev.pu.13.050192.001323. [DOI] [PubMed] [Google Scholar]

Articles from Bulletin of the World Health Organization are provided here courtesy of World Health Organization

RESOURCES